Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database
Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Gail J. Roboz(Cornell University), Maximilian Stahl(Harvard University), Hetty E. Carraway(Cleveland Clinic), David A. Sallman(Moffitt Cancer Center), Constantine Logothetis(Saint Louis University), Amy E. DeZern(Johns Hopkins University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Tariq Kewan(Yale University), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Maria L. Amaya(University of Colorado Denver), Jessica M. Stempel(University of New Haven), Zhuoer Xie(Mayo Clinic), Ondřej Bláha(Yale University), Michael R. Savona(Vanderbilt University), Mikkael A. Sekeres(University of Miami), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Benjamin Rolles(Brigham and Women's Hospital), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Christine M. McMahon(Albert Einstein College of Medicine), Hayley Hawkins(Vanderbilt University Medical Center), Pinkal Desai(NewYork–Presbyterian Hospital), Jaroslaw P. Maciejewski(Cleveland Clinic), Justin Grenet(Cornell University), Matteo Giovanni Della Porta(Humanitas University), Rory M. Shallis(Smilow Cancer Hospital), Amyah C. Harris(Dana-Farber Cancer Institute), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Andrew M. Brunner(Harvard University), Najla H. Al Ali(Moffitt Cancer Center), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k